Maiko Abumiya

1 Introduction BCR:ABL1 tyrosine kinase inhibitors (TKIs) improve the long-term life expectancy of patients with chronic myeloid leukemia (CML), similar to that of age-matched populations [1].

ORIGINAL ARTICLE Masatomo Miura PhD Corresponding Author m-miura@hos.akita-u.ac.jp orcid.org/0000-0001-7120-2425 Department of Pharmacy, Akita University Hospital, Akita, Japan Correspondence Masatomo Miura, Department of Pharmacy, Akita University Hospital, 1‐1‐1 Hondo, Akita 010‐8543, Japan.

CASE REPORT Naoto Takahashi MD, PhD Corresponding Author naotot@doc.med.akita-u.ac.jp orcid.org/0000-0002-6758-3787 Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan Correspondence Naoto Takahashi, Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, 1‐1‐1 Hondo, Akita City, Akita, 010‐8543, Japan.